March 11-13, 2021
To help you get as much value from NASH-TAG 2021 as possible, we have identified several presentations and articles we find most interesting. Our daily podcasts will summarize these and discuss what they suggest for the future of NASH/NAFLD therapies.
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeting. This conversation looks at the session covering fibrosis.
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeeting. This conversation looks at sessions covering epidemiology, public response and clinical questions.
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week’s Paris NASH meeting, an event with exciting scientific messages and insights.
S2-E45.3 – Discussing the EASL Guidelines and the Path to A Non-Invasive Testing Future with Donna Cryer
Global Liver Institute President and CEO Donna Cryer joins Roger Green to discuss why recent EASL guidelines around use of non-invasive tests (NITs) in Fatty Liver diagnosis and disease tracking is such an important step for patients and treaters alike.
Fatty Liver Foundation President Wayne Eskridge joins Louise Campbell and Roger Green to discuss why he is so enthusiastic about the FDA’s recent approval of the ELF test as a prognostic test for cirrhosis.
NASH kNOWledge President Anthony Villiotti joins Louise Campbell and Roger Green to highlight two recent publications about NAFLD/NASH prevalence (underestimated!) and patient awareness (miniscule!) and what that portends for the future.